Recombinant Human Thrombopoietin Completed Phase 3 Trials for Purpura / Idiopathic Thrombocytopenic Purpura Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT01506414Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)
NCT01525836rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP
NCT01734044rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP